Columbia Large Cap Growth ETF
REGS
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 290 Congress Street Boston United States of America 02210
- IPO Date
- Mar 18, 2026
- Website
- columbiathreadneedleus.com
- Similar Companies
- Business
- Regencell Bioscience Holdings Limited (NasdaqCM: REGS) is a bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (TCM) for neurocognitive disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The company offers therapeutic solutions derived from proprietary herbal formulations, such as its lead candidate RGC-02, a non-pharmaceutical treatment targeting cognitive and behavioral impairments; diagnostic tools for early screening of neurodevelopmental conditions; and clinical-stage interventions combining TCM extracts with behavioral therapies. Its product pipeline emphasizes safe, natural alternatives to conventional pharmaceuticals, targeting pediatric and adolescent populations through personalized treatment protocols. Founded in 2014 and headquartered in Causeway Bay, Hong Kong, Regencell operates primarily in Asia with clinical trials and partnerships spanning Hong Kong, China, and Southeast Asia, serving healthcare providers, clinics, and families seeking integrative neurocognitive care. In 2025, the company announced a major strategic expansion through a landmark funding round exceeding $50 million to accelerate Phase III trials for RGC-02 in ADHD; formed a key partnership with a leading TCM research institute in Beijing for ASD co-development; and launched a new subsidiary in Singapore for regional commercialization, marking its first entry into Southeast Asian markets. These initiatives follow a 2024 reorganization that streamlined its R&D operations and enhanced manufacturing capabilities at its Hong Kong facility to support scaled production.